FDA panel questions safety of female sex-dysfunction drug
“A federal advisory panel voted unanimously yesterday that the first drug to enhance the sex drive of women should not be approved because there is not enough information about its long-term safety.”
Not surprising in the wake of Vioxx and hormone replacement therapy. Expect the FDA to increasingly act on the side of caution.
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
